Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT03086330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus. A 30-week Randomised, Double-blind, Placebo-controlled Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i) monotherapy or in combination with either metformin or sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes. Subjects will remain on their pre-trial medication.
Study identification
- NCT ID
- NCT03086330
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 302 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2017 (Actual)
- Primary completion
- Jul 4, 2018 (Actual)
- Completion
- Aug 6, 2018 (Actual)
- Last update posted
- Jul 2, 2021
2017 – 2018
United States locations
- U.S. sites
- 43
- U.S. states
- 19
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Andalusia | Alabama | 36420 | — |
| Novo Nordisk Investigational Site | Anniston | Alabama | 36207 | — |
| Novo Nordisk Investigational Site | Glendale | Arizona | 85308 | — |
| Novo Nordisk Investigational Site | Phoenix | Arizona | 85037 | — |
| Novo Nordisk Investigational Site | Tempe | Arizona | 85283 | — |
| Novo Nordisk Investigational Site | Little Rock | Arkansas | 72211 | — |
| Novo Nordisk Investigational Site | La Jolla | California | 92037 | — |
| Novo Nordisk Investigational Site | Lincoln | California | 95648 | — |
| Novo Nordisk Investigational Site | Northridge | California | 91325 | — |
| Novo Nordisk Investigational Site | Edgewater | Florida | 32132 | — |
| Novo Nordisk Investigational Site | Maitland | Florida | 32751-4422 | — |
| Novo Nordisk Investigational Site | Lawrenceville | Georgia | 30046 | — |
| Novo Nordisk Investigational Site | Woodstock | Georgia | 30189-4255 | — |
| Novo Nordisk Investigational Site | Hutchinson | Kansas | 67502-1131 | — |
| Novo Nordisk Investigational Site | Lexington | Kentucky | 40503 | — |
| Novo Nordisk Investigational Site | Baltimore | Maryland | 21204 | — |
| Novo Nordisk Investigational Site | Troy | Michigan | 48098 | — |
| Novo Nordisk Investigational Site | Jefferson City | Missouri | 65109 | — |
| Novo Nordisk Investigational Site | Albany | New York | 12206 | — |
| Novo Nordisk Investigational Site | Smithtown | New York | 11787 | — |
| Novo Nordisk Investigational Site | West Seneca | New York | 14224 | — |
| Novo Nordisk Investigational Site | Charlotte | North Carolina | 28207 | — |
| Novo Nordisk Investigational Site | Charlotte | North Carolina | 28226 | — |
| Novo Nordisk Investigational Site | Gastonia | North Carolina | 28054 | — |
| Novo Nordisk Investigational Site | Greenville | North Carolina | 27834 | — |
| Novo Nordisk Investigational Site | Kinston | North Carolina | 28501 | — |
| Novo Nordisk Investigational Site | Morehead City | North Carolina | 28557-4346 | — |
| Novo Nordisk Investigational Site | Norman | Oklahoma | 73069 | — |
| Novo Nordisk Investigational Site | Beaver | Pennsylvania | 15009 | — |
| Novo Nordisk Investigational Site | McMurray | Pennsylvania | 15317 | — |
| Novo Nordisk Investigational Site | Pittsburgh | Pennsylvania | 15243 | — |
| Novo Nordisk Investigational Site | Arlington | Texas | 76012-4637 | — |
| Novo Nordisk Investigational Site | Austin | Texas | 78745 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75208 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75231 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77081 | — |
| Novo Nordisk Investigational Site | Irving | Texas | 75061-2210 | — |
| Novo Nordisk Investigational Site | Shavano Park | Texas | 78231 | — |
| Novo Nordisk Investigational Site | Sugar Land | Texas | 77479 | — |
| Novo Nordisk Investigational Site | Victoria | Texas | 77901 | — |
| Novo Nordisk Investigational Site | Murray | Utah | 84123 | — |
| Novo Nordisk Investigational Site | Chesapeake | Virginia | 23321 | — |
| Novo Nordisk Investigational Site | Olympia | Washington | 98502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03086330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2021 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03086330 live on ClinicalTrials.gov.